Premium Staffing Solutions’ Post

The Biopharma UK/ Europe Opportunity: Strategic Partnering and M&A Considerations Typically, biopharma companies, as they grow from small to mid-size, focus their efforts on the US and their market of origin for commercial launch. As traction for their products and services grow, the next step is to expand into other geographies either organically or inorganically, through strategic partnering and M&A. For those non-European biopharmas, capturing opportunities in UK and Europe is often their next priority, given this combined geography accounts for over 20 per cent of the total global pharma market. The challenge with this geographic expansion is that UK/ Europe presents a complex and highly fragmented landscape: 31 markets within the European Union (EU), requiring European Medicines Agency (EMA) approval, as well as other markets with their own regulatory authorities, such as Switzerland with Swissmedic; also the MHRA in UK has developed its own standards to distinguish itself from EMA. There are also distinct healthcare systems and reimbursement processes for each market. Consequently, for many non-European life science firms, expanding their products and services in Europe is not straightforward. In our view, non-European biopharma players can tackle these challenges head-on as they expand into UK/ Europe markets: - Establish market credibility: Lack of brand recognition among target companies can make it challenging to secure a deal. In a horizon scan for a Japanese CRO client, one of the identified targets was unable to relate to potential outbound opportunities from a minority investment deal; brand building and market shaping efforts are critical prior to anticipated entry. - Test your value proposition with potential customers and partners in Europe to understand positioning vis-à-vis the competition prior to entry. Validating the value proposition through confidential external interviews, conducted on your behalf, prior to potential target discussions can be useful to deliver optimal selling messages to potential targets. - Consider investing in pre-deal diligence: Deal cycles are often shorter in promising opportunity areas with higher levels of sector consolidation. Heightened investor interest could mean that target assets are approached quickly to avoid opportunities being missed. An investment in pre-deal diligence can help pre-qualify investment goals, supported by an initial revenue forecast and valuation of the target, prior to target approach. Many investor and life science business development teams are attempting to develop go-to-market strategies for UK/ Europe expansion given the size of the opportunities. An external, independent view on European market dynamics, and value creation opportunities and targets to pursue, will help them to secure sustainable partnering outcomes. #life sciences deals #strategic partnering and M&A #EU market entry #life sciences M&A

As the global pharmaceutical and biotech industry faces challenges, including layoffs at companies like Grifols, Takeda, and Thermo Fisher, it is important to highlight that Poland continues to offer a stable and resilient environment for business development and investment.   Danish Leo Pharma has recently announced that it will cut down on staff in its global operations. Around 200 positions will be cut, while 50 will be moved to Poland.   While we observe necessary adjustments across Europe, Poland's commitment to innovation, talent development, and a favourable business climate, positions it as a reliable partner for companies looking to expand and thrive.   The Polish market offers not only a skilled workforce but also increasing opportunities in key sectors like life sciences and technology.   At Penteris, we continue to see international businesses choosing Poland as a strategic location for growth, and we are proud to support them every step of the way.   #penteris #poland #pharmaceuticalindustry #businessresilience #legalsupport #investment #lifesciences #bigpharma #businessopportunity

This week, we achieved a significant milestone with the official opening of the Innovation Capability Center (ICC) Mexico. The ICC Mexico is the second of three ICCs aimed at enhancing our digital and technological capabilities. Our space is designed with a focus on environmental sustainability, providing an exceptional employee experience and fostering creativity, innovation, and collaboration within our team. This achievement coincides with our 60th anniversary in Mexico, demonstrating our dedication to strengthening our presence in the country through data and digital innovation. The opening was celebrated with internal members and our partners, including the honorable presence of Minister of Japanese Embassy Hirota Tsukasa. Currently, the ICC Mexico accommodates over 100 passionate professionals from diverse backgrounds. As we continue to expand our footprint in Mexico, this milestone is one step on our path to become one of the most trusted, science-driven, digital biopharmaceutical companies.  As we continue to grow, join our team and be part of the transformation and exciting journey at https://lnkd.in/eQ7Gcmu7 #ICCMexico #Innovation #DigitalTransformation

🌟Transitioning from one industry to another 🌟 At #DaiichiSankyoEurope our employees hold shared values and together help drive us towards our vision 🌍 Today, we’re excited to highlight the career journey of Andrea Ortiz, Operational Buyer Specialist at Daiichi Sankyo España. After transitioning to the pharmaceutical industry from her previous role, Andrea has experienced challenges, but also many rewarding moments and opportunities for growth ✨ Curious to hear more about what motivated this career shift and how Andrea navigated the transition? Read more in the Q&A below! 👇 #CareerJourney #CareerInsights #OurPeople

Pfizer has announced cost cutting measures to the tune of USD 1.5 billion in May, including significant layoffs across facilities in Belgium, Ireland and North Carolina. During the pandemic years, Pfizer’s revenue doubled to $100.3 billion, prompting rapid expansions. However, now that the prevalence of COVID-19 is declining, demand for the vaccine is also decreasing, resulting in the need to reconsider operational spending. Is there a lesson to be learnt from the story of Pfizer's rapid expansion and subsequent rollback? Ensuring that the IPA attracts a diversified portfolio of industries and has proactive aftercare support in place will help minimize the impact on the local economy when FDI projects are scaled back. #fdi #investmentpromotion #pharmaceuticals #ViewfromtheCenter

Interesting move from AstraZeneca manufacturing and supply chains. Consider for a moment that in the full 2023 results, the US was 42% of global sales. Emerging Markets were 26%, Established Rest of World 11% and Europe 21%. Given the tensions between the US and China, this seems like a good business move to safeguard supply to 42% of AZ's sales. I don't know if other players are doing this or thinking of doing it. I always felt that from my time at AZ, we were ahead of the curve on so many business and commercial initiatives. The rest often followed. I will watch with interest how this move by AZ works out.

Great insights on the evolving landscape of EU Pharmaceutical regulations and the critical role of investing in people. It’s inspiring to see how the Europe & Canada region is leading the way in healthcare innovation. #innovation #people

Hello Folks...📢 Hope you will get great insights and it's urge to you; Add your valuable insights or beat of knowledge for towards learning. 🌍 Exploring International Markets in the Pharmaceutical Industry: Key Insights & Strategies In the dynamic landscape of global pharmaceuticals, understanding region-specific strategies is crucial for success. Here’s a quick dive into market entry strategies, regulatory environments, and opportunities across key regions: 🇺🇸 North America: The U.S. demands stringent FDA compliance, but partnerships and innovation (like Pfizer's generics expansion) open doors. In Canada, leveraging U.S. standards accelerates entry, as seen with AstraZeneca's streamlined drug approvals. 🇩🇪 Europe: Centralized EMA approvals simplify EU market access. Germany's appetite for biosimilars (e.g., Sandoz) and France's focus on innovative drugs present significant opportunities. 🇨🇳 Asia-Pacific: In China, joint ventures (like Eli Lilly's with Innovent) are key, while India’s generics market offers massive potential. Japan's aging population creates demand for advanced therapies. 🇦🇪 Middle East: Saudi Arabia and the UAE are ripe for high-end pharmaceuticals, with companies like Novartis establishing regional offices to strengthen market presence. 🇧🇷 Latin America: Brazil and Mexico offer growth in generics, with partnerships and regional trade agreements playing a pivotal role, as demonstrated by Sanofi's vaccine strategies. 🇿🇦 Africa: South Africa and Nigeria's focus on essential medicines and vaccines (e.g., J&J's public-private partnerships) offer substantial opportunities for impact. 🇷🇺 CIS: Russia's local production policies encourage joint ventures, while Kazakhstan's EAEU alignment opens doors for strategic partnerships. Navigating these diverse markets requires tailored strategies, deep regulatory understanding, and the ability to adapt. By leveraging local partnerships and focusing on region-specific demands, pharmaceutical companies can unlock significant growth and innovation globally. 💊🌐 #Pharmaceuticals #GlobalMarket #InternationalBusiness #HealthcareInnovation #RegulatoryAffairs #MarketEntry

Regional supply chains are growing in popularity as businesses implement their supply chain resilience plans. Learn how AstraZeneca, a BioPharmaceutical company, is developing two distinct supply chains - one for Asia and another serving Western countries. Article and video interview with AstraZeneca CEO Pascal Soriot from Yahoo Finance: https://lnkd.in/gBQtNG3d #supplychain #supplychainnews #supplychainresilience #medicalsupplychains #astrazeneca #pharma

💊Pharma Deal Alert ⏰. 💰 Novo Holdings, the asset manager for the foundation that oversees Novo Nordisk, will acquire Catalent, a leading contract development and manufacturing organization (CDMO), for $16.5 billion. 💊 Here's the scoop: Novo Nordisk will recoup two-thirds of the cost by purchasing three Catalent fill-finish sites for $11 billion upfront. The strategic move is aimed at meeting soaring demand for its blockbuster drugs Wegovy® and Ozempic®. 📦The acquired sites in Bloomington, IN; Brussels, Belgium; and Anagni, Italy, employ more than 3,000 people and will strengthen Novo Nordisk's supply chain capabilities. 🚧 This acquisition reflects a broader trend in the industry, where companies are emphasizing strategic acquisitions and increasing M&A activity to stay ahead in a dynamic market landscape. ************************************* Source: https://buff.ly/49gBIcz Digitalize your M&A process now: https://buff.ly/3MABeE0 #mergersandacquisitions #duediligence #carveout #digitalsmart